Greenberg Traurig examines role of patent portfolios in life sciences sector
Greenberg Traurig published an analysis exploring why patent portfolios remain a critical strategic asset for life sciences companies operating in highly regulated and capital-intensive markets.
The article was written by David Dykeman, Co-Managing Shareholder of GT’s Boston office and co-chair of the firm’s global Life Sciences & Medical Technology Group. He discusses how patents can help innovators protect research and development investments, reduce competitive risk, attract investors, and create licensing and commercialization opportunities over long product-development cycles.
The article also notes that intellectual property strategy can play a significant role in valuation and market positioning as companies advance technologies through clinical and regulatory stages.
Read the full analysis here.
